Natural Resources for Human Health
eISSN: 2583-1194

Original Research

Received 10 March 2026
Revised 22 April 2026
Accepted 10 May 2026

Natural Resources for Human Health 2026, Vol. 6 (3): 536–543

KEYWORDS:
Coconut water; Synbiotic beverage; Probiotics; Prebiotics; Inulin; Lactiplantibacillus plantarum; Gut microbiome; Bowel regularity; Functional constipation; Bifidobacterium.

Synbiotic Coconut Water Beverage for Improving Bowel Regularity and Microbiome Composition

Sheetal Sharma[1], Karabi Kalita[2], Deepak Bhanot[3], Jeniffer Raj[4], Biloliddin Zuxriddinov[5], Anitha S[6], Subhashini K[7]

[1]Department of Pharmacy, Vivekananda Global University, Jaipur, India. sheetal.sharma@vgu.ac.in
[2]School of Pharmacy and Research, Dev Bhoomi Uttarakhand University. sopr.karabi@dbuu.ac.in
[3]Centre for Research Impact & Outcome, Chitkara University Institute of Engineering and Technology, Chitkara University, Rajpura, 140401, Punjab, India. deepak.bhanot.orp@chitkara.edu.in
[4]Department of Microbiology, Vinayaka Missions Medical College, Karaikal, Vinayaka Mission's Research Foundation (DU), Tamil Nadu, India. yedlabala@yahoo.co.in
[5]Central Asian University, Tashkent, Uzbekistan. biloliddin18092007@gmail.com
[6]Department of Microbiology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research, Enathur, Kanchipuram, Tamil Nadu 631552, India. anithasmicro@maher.ac.in
[7]Department of Pharmacology, Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research, India. subhashinipharma@maher.ac.in

ABSTRACT:

Background: A palatable synbiotic drink may offer a low-burden dietary approach to bowel regularity.

Objective: To evaluate coconut water fermented with Lactiplantibacillus plantarum and supplemented with inulin in comparison with pasteurized coconut water without live cultures or inulin using a randomized controlled microbiome trial.

Methods: The draft protocol included 80 experimental units or participants involving adults with functional constipation. The intervention was administered or tested for 8 weeks. The primary outcome was spontaneous complete bowel movements per week, with additional assessment of stool consistency, Bifidobacterium abundance, fecal short-chain fatty acids, gastrointestinal quality-of-life score. Standardized laboratory, clinical, or food-analysis procedures were applied, and between-condition effects were evaluated with two-sided tests at $\alpha=0.05$.

Results: The synbiotic coconut water beverage increased spontaneous complete bowel movements from 2.1 ± 0.8 to 5.0 ± 1.4 per week, compared with an increase to 2.9 ± 1.1 in controls ($p<0.001$). Bifidobacterium abundance increased by 4.1 percentage points, fecal acetate and butyrate rose significantly, and gastrointestinal quality-of-life scores improved by 22.6%. Direction and magnitude of the dummy results were internally consistent between primary and secondary endpoints and tolerability or assay-quality standards were acceptable.

Natural Resources for Human Health
eISSN: 2583-1194

Conclusion: The example data indicates that coconut water fermented with Lactiplantibacillus plantarum and inulin added may result in a significant change in spontaneous complete bowel movements per week with combined probiotic delivery and selective fermentation of inulin in a mineral-enriched beverage. These results are only meant as a thorough manuscript-development illustration and should be substituted with ethically produced, independently tested observations prior to being submitted to science.

1. INTRODUCTION

Synbiotic Coconut Water Beverage to Improve Bowel Regularity and Microbiome Composition poses a key research question at the convergence of experimental pharmacology, nutritional science, and translational health studies. Relevant published work has provided a scientific basis to assess the coconut water fermented with Lactiplantibacillus plantarum and inulin supplemented on the basis of spontaneous complete bowel movements per week [1]. However, the differences in preparation, exposure, choice of comparators and definition of outcomes still render the reliability of cross-study comparisons with confidence.

A second piece of evidence is in favor of the biological plausibility of the current hypothesis. Functional or biochemical activity has been previously reported in the studies of coconut water and related interventions, all in a direction that is consistent with the direction of benefit proposed [2]. Such observations provide a reason to test them formally, but they do not exclude the use of standardized materials and predetermined criteria of analysis.

Beyond the natural-product and functional-food literature, reproducibility has been found to be determined by chemical characterization, processing conditions, dose, biological matrix and stability of active constituents [3]. To conduct the current study, coconut water fermented with Lactiplantibacillus plantarum and inulin added was thus considered a research grade intervention as opposed to an undefined traditional or commercial preparation.

The suggested mechanism implies that a mixture of probiotics should be delivered and that the inulin should be selectively fermented in a mineral-enriched beverage matrix. Evidence in the literature suggests that related biological responses usually entail, but are not limited to, interacting redox, inflammatory, metabolic, microbial, enzymatic, or differentiation pathways [4]. Measuring a primary functional endpoint together with mechanistic markers can therefore provide a more coherent interpretation.

Outcome assessment also requires methods suited to the study model. Established laboratory or clinical methodology emphasizes standardized sample handling, validated analytical procedures, appropriate controls, and prespecified interpretation thresholds [5]. These principles guided selection of spontaneous complete bowel movements per week as the primary outcome and the accompanying secondary endpoints.

Changes in spontaneous complete bowel movements per week are most convincing when they are accompanied by concordant changes in stool consistency and Bifidobacterium abundance. Related research has demonstrated the value of combining functional, biochemical, and structural outcomes when evaluating complex botanical, microbial, or food-based interventions [6].

Safety and quality are equally important. Natural origin does not guarantee consistent composition or freedom from adverse effects, contaminants, interactions, or degradation, and published pharmacovigilance and quality-control evidence recommends integrating these considerations from the beginning of product development [7].

Finally, transparent study design is necessary to reduce bias. Guidance and prior methodological research relevant to the present experimental model support randomization, blinding where feasible, replication, complete accounting of exclusions, and reporting of effect estimates rather than reliance on p-values alone [8].

Despite the available evidence, few studies have combined a clearly defined coconut water fermented with Lactiplantibacillus plantarum and supplemented with inulin, an appropriate comparator, a prespecified primary endpoint, and supporting mechanistic or feasibility outcomes in adults with functional constipation. The aim of this study was therefore to determine the

effect of coconut water fermented with Lactiplantibacillus plantarum and supplemented with inulin on spontaneous complete bowel movements per week compared with pasteurized coconut water without live cultures or inulin. Secondary outcomes included assessing stool consistency, Bifidobacterium spp abundance, fecal short-chain fatty acids, and quality or safety indicators.

2. MATERIALS AND METHODS

2.1. Study design and setting

The present manuscript reports a prespecified randomized parallel-group microbiome trial that was conducted in adults with functional constipation. The intended sample size is 80 experimental units or participants and was designed to compose a comparison between coconut water fermented with Lactiplantibacillus plantarum and inulin-supplemented and pasteurized coconut water with live cultures or without. The observation period was 8 weeks. Any numerical data in this manuscript constitute dummy/example data designed to be prepared to draft, demonstrate statistically, prepare tables and calculate graphs; they are not the results of observations on a completed investigation. The design still adheres to realistic laboratory or clinical protocols such that the draft can be converted to an approved protocol and substituted with actual measurements in the future.

2.2. Participants

Potential subjects were adults or youths who fit the target population: adults having functional constipation. Inclusion meant that there had to be stable health or stable background treatment, willingness to be on regular diet and activity and the capability to attend all assessment visits. Exclusion criteria were pregnancy, major organ disease, intake of antibiotics or probiotics within the past year when applicable, intake of supplements that had the potential to affect the main outcome measurement, allergic to the study materials or enrolled in another intervention study. Informed consent and in some cases assent and guardian consent would be obligated in writing to a real trial.

2.3. Randomization, allocation, and intervention

They were conceptually randomized in a 1:1 ratio based on variable block size, the allocation was concealed in sequentially numbered opaque envelopes or an electronic system. The experimental condition was fermented coconut water with Lactiplantibacillus plantarum and inulin; the control condition was pasteurized coconut water, which did not contain live cultures and inulin. The products were packed into similar looking containers encoded and with similar instructions. They were requested to continue with habitual dieting, medications, and exercise, the number of unused products and daily records were used to determine adherence estimates.

2.4. Outcome assessment

The main finding was spontaneous complete bowel movements/week which was in the form of events/week. Secondary were stool consistency, Bifidobacterium abundance, fecal short-chain fatty acids, gastrointestinal quality-of-life score. Depending on the design, measurements would be at baseline and follow-up or across conditions of concentration and time. Assays were conducted as specified in validated kit protocols or standardized analysis procedures and redundant measurements were repeated where the coefficient of variation was greater than 10%. The results of the clinical measurements were recorded following standardized rest period and the outcomes of the food-products were determined under controlled serving conditions.

2.5. Quality assurance and bias control

Laboratory or trial procedures were defined in a written sample labeling, timing, calibration, data entry, and protocol deviation form. Whenever feasible, outcome assessors were blinded. Ten percent of records were conceptually revisited with source data and analytical runs were not accepted until calibration and quality-control samples proved within predefined limits. The primary complete-case display did not impute the missing values and sensitivity analyses were based on intention-to-treat framework or model-based estimation where applicable.

2.6. Sample-size rationale

To have an example of a manuscript development, the sample of 80 units was chosen as the planned sample. In the case of a real study, the computation would be substituted by one derived on the basis of a pilot-obtained standard deviation and the

minimal clinically or biologically significant difference between spontaneous complete bowel movements each week. This last calculation must indicate two sided α=0.05, power of at least 80% is desired, allocation ratio, expected attrition or unusable assays and any repetition, clustering or multiple primary comparison adjustment

2.7. Statistical analysis

Mean standard deviation were used to summarize continuous data that were approximately normally distributed, and median interquartile range were used to summarize skewed data. Categorical results were presented in terms of number and percentage. Independent t tests, Mann-Whitney tests, chi-square tests, or Fisher exact tests were used to compare the results between-groups in the baseline. Dependent variables were evaluated by analyzing covariance, repeated measures, mixed effects models, one-way analysis of variance with multiplicity adjusted post hoc comparisons or nonparametric equivalents based on the study design. Effect estimates were accompanied by 95% confidence intervals. Correlations used Pearson or Spearman coefficients. All tests were two-sided, and $p<0.05$ was considered statistically significant. Analyses were conceptually performed in a current statistical package with an auditable syntax file.

3. RESULTS

The analysis included the full dummy/example dataset specified for the randomized parallel-group microbiome trial. Baseline characteristics, assay controls, or starting values were balanced across comparison conditions, and no predefined quality-control run was rejected. The tables present mean ± standard deviation unless another summary is stated. Because the data are illustrative, participant flow, assay exclusions, and p-values were generated to be statistically coherent rather than to represent an actual enrolled sample.

The synbiotic coconut water beverage increased spontaneous complete bowel movements from 2.1 ± 0.8 to 5.0 ± 1.4 per week, compared with an increase to 2.9 ± 1.1 in controls ($p<0.001$).

Table 1. Baseline characteristics and beverage exposure

Characteristic	Intervention	Control	p-value
Participants (n)	40	40	—
Age (years)	38.6 ± 8.2	39.1 ± 8.0	0.79
Female n (%)	24 (60.0)	23 (58.0)	0.86
Habitual fiber (g/day)	14.2 ± 3.1	14.5 ± 3.0	0.68
Beverage adherence (%)	93.1 ± 5.4	92.2 ± 5.9	0.47

Values are dummy/example data presented as mean ± SD unless otherwise stated.

The alteration of stool consistency and Bifidobacterium abundance helped to support the direction of the primary effect. The change in the magnitude of response typically escalated with exposure to intervention or higher at the follow-up within the intervention arm, but the comparator exhibited smaller variations. The group-by-time or condition effect was also significant when there were repetitions and when baseline values and planned multiple comparisons were adjusted.

Table 2. Microbiome and clinical outcomes

Outcome	Intervention baseline	Intervention end	Control baseline	Control end	p for interaction
Complete bowel movements/week	2.1 ± 0.4	5.0 ± 0.4	2.2 ± 0.4	2.9 ± 0.4	<0.001
Bifidobacterium (%)	5.1 ± 1.3	9.2 ± 1.8	5.0 ± 1.2	5.6 ± 1.4	<0.001
Fecal butyrate (mmol/kg)	9.8 ± 2.1	12.6 ± 2.4	9.7 ± 2.0	10.1 ± 2.1	0.002
GI symptom score	5.8 ± 2.0	4.4 ± 1.8	5.7 ± 2.1	5.3 ± 2.0	0.018

Values are dummy/example data presented as mean ± SD unless otherwise stated.

Bifidobacterium levels improved by 4.1 percentage points, fecal acetate and butyrate levels increased, and gastrointestinal quality-of-life scores improved by 22.6%.




Figure 1. Primary outcome based on dummy/example data.

Exploratory analyses have shown that most relevant mechanistic marker was related to response in spontaneous complete bowel movements per week. The trend was in line with a combined probiotic formulation and selective fermentation of inulin in a mineral-fortified beverage formulation. No extreme value altered the direction of the result in sensitivity analysis. For clinical and food studies, adherence and acceptability remained within predefined feasibility limits; for laboratory studies, replicate variation and control performance remained within the planned analytical range.

Table 3. Taxonomic and functional changes

Outcome	Intervention change	Control change	Adjusted difference	p-value
Lactobacillus (%)	+2.8 ± 1.5	+0.3 ± 1.1	+2.5	<0.001
Bifidobacterium (%)	+4.1 ± 1.8	+0.6 ± 1.3	+3.5	<0.001
Acetate (mmol/kg)	+9.4 ± 6.2	+1.8 ± 5.1	+7.6	0.004
Alpha-diversity responders n (%)	27 (68.0)	14 (35.0)	—	0.006
Overall acceptability / 9	7.6 ± 0.7	7.5 ± 0.8	+0.1	0.54

Values are dummy/example data presented as mean ± SD unless otherwise stated.




Figure 2. Secondary or mechanistic outcome based on dummy/example data.

No unexpected safety signal was present in the example dataset. Mild events or assay artifacts were infrequent and balanced, and there were no serious adverse events, unplanned deaths, contamination failures, or invalid control runs unless explicitly shown in the tables. These observations are illustrative and must not be interpreted as evidence of real-world safety.

4. DISCUSSION

The present manuscript-development study indicates that coconut water fermented with Lactiplantibacillus plantarum and supplemented with inulin may improve spontaneous complete bowel movements per week compared with pasteurized coconut water without live cultures or inulin. Concordant alterations in stool consistency, Bifidobacterium abundance, and fecal short-chain fatty acids reinforced the finding of the dummy. This consistency within the firm is significant since inter-endpoint agreement between functional and mechanistic end-points is less apt to represent some form of solitary analytical difference.

The overall direction of the main finding is generally in line with other published studies of standardized botanical/food-derived interventions in similar models [9]. Despite the variations in protocol and population, that literature also suggests that the quality of preparation and dose can significantly affect the magnitude of response.

Similar studies have also noted alterations in inflammatory, oxidative, metabolic, microbial, structural or functional outcomes, which justify multidimensional assessments and not the use of a single surrogate [10]. The current trend thus fits a broader realm of evidence and yet is specific to the intervention and model under consideration.

The convergent pathways and matrix-dependent effects that research has shown complex interventions to have support the mechanistic interpretation [11]. In this study, the association between the primary response and supporting markers was compatible with combined probiotic delivery and selective fermentation of inulin within a mineral-rich beverage matrix; however, association alone cannot prove mediation or identify the active constituent.

Prior work using related endpoints further supports the clinical or biological relevance of stool consistency and Bifidobacterium abundance [12]. Their concomitant enhancement reinforces the hypothesis, yet confirmatory studies with this hypothesis in future must specify the characteristics of these variables as secondary results, mechanistic mediators, or exploratory biomarkers.

The magnitude of the effect on the example ought to be understood within the framework of previous intervention studies and evidence syntheses in the general area [13]. This size was chosen deliberately in order to be realistic and there was overlap among individuals or replicates since pilot effects often decrease in larger independent samples.

Methodological evidence highlights the need to use standardized measurements, suitable conditions of comparison and transparent reporting in the study of complex interventions [14]. Biases can be mitigated by replication, allocation concealment, blinded assessment, crossover control or validated analytical calibration but none of these will eliminate all sources of error.

Tolerability, quality assurance, product stability, adherence and interactions with a habitual diet or medication are also critical to long-term translation. The available safety and implementation literature advises to consider these factors and efficacy together in contrast to obtaining a positive initial outcome [15].

The paper has a number of limitations. To begin with, the numerical data is descriptive and cannot be used to make a scientific assertion. Second, the suggested sample and timeframe might not detect rare adverse incidents or prolonged adjustment. Third, surrogate outcomes may not necessarily be converted to patient-important benefits. Fourth, response may be altered by unmeasured diet, genetic, microbial, environmental, harvest or manufacturing variables.

The next phase should involve independent analytical validation, dose-ranging, preregistration, sufficient power and a predetermined statistical analysis plan. The ethics approval, trial registration, allocation procedures, adherence and intention-to-treat analysis should be documented in clinical studies. Preclinical trials ought to be reported containing randomization, blinding, humane endpoints, exclusions, and batch chemical fingerprints.

Translating to diet, a drinkable synbiotic could be a low-burden dietary intervention to bowel regularity. The intervention is to be viewed as a possible addition or research lead but not a substitute to existing care. Further development should be based on replication, safety, cost, standardization, acceptability and comparison with the alternatives available.

In general, the sample results confirm the research hypothesis and present a logical framework of a true study. All numerical outputs, ethics statements, registration information, disclosure and analysis must be substituted or checked with the actual study record prior to scientific submission.

5. CONCLUSION

In this full manuscript draft with dummy/example data, fermentation of coconut water with Lactiplantibacillus plantarum and addition of inulin elicited a desirable shift in spontaneous complete bowel movements per week versus pasteurized coconut water with no live cultures or inulin, accompanied by shift in stool consistency, abundance of Bifidobacterium, and fecal short-chain fatty acids. The trend was similar to combined probiotic delivery and selective inulin fermentation in a mineral-enriched beverage system and implied possible applicability since a palatable synbiotic beverage has the potential to be a low-burden dietary intervention to bowel regularity. Development of protocols, data-collection plans and subsequent work on the manuscript are based upon the draft; all numerical data should be substituted with a data produced by ethical means and independently verified, and then the work can be considered as a research.

Declarations for Completion Before Submission

Ethics approval: Insert the actual institutional ethics committee name, approval number, approval date, and relevant consent or animal-welfare statement.

Trial registration: Insert the registry name and number for prospective clinical trials, where applicable.

Funding: Insert the verified funding source or state that no specific funding was received.

Conflicts of interest: Insert author-specific conflict-of-interest disclosures.

Data availability: Describe where the actual de-identified dataset and analysis code will be available.

Author contributions: Insert contribution statements using an accepted taxonomy such as CRediT.

REFERENCES

[1] Hill C, Guarner F, Reid G, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi:10.1038/nrgastro.2014.66. PMID:24912386.

[2] Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: the International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491-502. doi:10.1038/nrgastro.2017.75. PMID:28611480.

[3] Swanson KS, Gibson GR, Hutkins R, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the definition and scope of synbiotics. Nat Rev Gastroenterol Hepatol. 2020;17(11):687-701. doi:10.1038/s41575-020-0344-2. PMID:32826966.

[4] Ekor M. The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Pharmacol. 2014;4:177. doi:10.3389/fphar.2013.00177. PMID:24454289.

[5] Marco ML, Heeney D, Binda S, et al. Health benefits of fermented foods: microbiota and beyond. Curr Opin Biotechnol. 2017;44:94-102. doi:10.1016/j.copbio.2016.11.010. PMID:27998788.

[6] Ulven SM, Holven KB, Gil A, Rangel-Huerta OD. Milk and dairy product consumption and inflammatory biomarkers: an updated systematic review of randomized clinical trials. Adv Nutr. 2019;10(suppl_2):S239-S250. doi:10.1093/advances/nmy072. PMID:31089732.

[7] Reynolds A, Mann J, Cummings J, Winter N, Mete E, Te Morenga L. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434-445. doi:10.1016/S0140-6736(18)31809-9. PMID:30638909.

[8] Mudryj AN, Yu N, Aukema HM. Nutritional and health benefits of pulses. Appl Physiol Nutr Metab. 2014;39(11):1197-1204. doi:10.1139/apnm-2013-0557. PMID:25061763.

[9] Jenkins DJA, Wolever TMS, Taylor RH, et al. Glycemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr. 1981;34(3):362-366. doi:10.1093/ajcn/34.3.362. PMID:6259925.

[10] Brouns F, Bjorck I, Frayn KN, et al. Glycaemic index methodology. Nutr Res Rev. 2005;18(1):145-171. doi:10.1079/NRR2005100. PMID:19079901.

[11] Ayaz A, Akyol A, Inan-Eroglu E, Kabasakal Cetin A, Samur G, Akbiyik F. Chia seed added yogurt reduces short-term food intake and increases satiety: randomized controlled trial. Nutr Res Pract. 2017;11(5):412-418. doi:10.4162/nrp.2017.11.5.412. PMID:28989578.

[12] Ho H, Lee AS, Jovanovski E, Jenkins AL, DeSouza R, Vuksan V. Effect of whole and ground Salba seeds on postprandial glycemia in healthy volunteers: a randomized controlled dose-response trial. Eur J Clin Nutr. 2013;67(7):786-788. doi:10.1038/ejcn.2013.103.

[13] Prior RL, Wu X, Schaich K. Standardized methods for the determination of antioxidant capacity and phenolics in foods and dietary supplements. J Agric Food Chem. 2005;53(10):4290-4302. doi:10.1021/jf0502698. PMID:15884874.

[14] Sies H. Oxidative stress: a concept in redox biology and medicine. Redox Biol. 2015;4:180-183. doi:10.1016/j.redox.2015.01.002. PMID:25588755.

[15] Yong CC, Yoon Y, Yoo HS, Oh S. Effect of Lactobacillus fermentation on anti-inflammatory potential of turmeric. J Microbiol Biotechnol. 2019;29(10):1561-1569. doi:10.4014/jmb.1906.06032. PMID:31434176.